Amneal Pharmaceuticals, Inc. (AMRX) has 10 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 2 sales totalling $6.3M. Most recent filing: Sept. 14, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 14, 2026 filed Sept. 11, 2026 | BUCHI J KEVIN Director | $295,430 | 40,890 | — | No | |
|
|
||||||
| Sept. 2, 2026 filed Sept. 1, 2026 | BOYER ANDREW S Executive Vice President | $0 | 80,000 | −29% | No | |
|
|
||||||
| Aug. 25, 2026 filed Aug. 21, 2026 | BOYER ANDREW S Executive Vice President | $0 | 152,426 | −36% | No | |
|
|
||||||
| Aug. 13, 2026 filed Aug. 11, 2026 | Daly Jason B. EVP, Chief Legal Officer | −$3,771,050 | 216,613 | −86% | No | |
|
|
||||||
| Aug. 13, 2026 filed Aug. 12, 2026 | Shah Nikita Executive Vice President | −$2,563,517 | 146,403 | −37% | No | |
|
|
||||||
Showing the 5 most recent of 10 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free